Serina Therapeutics, Inc. (SER): debt financing — AgeX draws $500K, sets warrant dividend and reverse split for Serina merger

Serina Therapeutics, Inc.

Drew $500,000 under secured convertible note with Juvenescence; repayment due May 9, 2024.
Declared warrant dividend: three Post-Merger Warrants per five shares held, exercise price $13.20, expiring July 31, 2025.
Reverse stock split expected March 14, 2024; trading on split-adjusted basis March 15, 2024.
Special meeting on March 14, 2024 to vote on warrant dividend and reverse stock split.

item 2.03 item 8.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Serina Therapeutics, Inc. incurred loan of $500,000 with Juvenescence Limited maturing May 9, 2024.

Instrument: loan
Principal: $500,000
Counterparty: Juvenescence Limited
Maturity: May 9, 2024
Event: incurrence

Exact text from the filing

On March 5, 2024, AgeX Therapeutics, Inc., a Delaware corporation (“AgeX”), drew $500,000 of its credit available under the Amended and Restated Secured Convertible Promissory Note, as amended ( the “Secured Note”), with Juvenescence Limited.

View on SEC.gov

299 debt financings filed in the last 30 days. Browse all debt financings →

Serina Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-009224

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.